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The Centers for Disease Control and Prevention (CDC) 
funded  the  Colorectal  Cancer  Screening  Demonstration 
Program  in  2005.  To  assess  the  feasibility  of  providing 
community-based  colorectal  cancer  screening,  CDC  is 
conducting a multiple-case study as part of a larger evalu-
ation  effort.  This  article  highlights  key  facilitators  and 
challenges common to the five programs studied during 
the start-up period.
Methods
The multiple-case study that includes all five program 
sites is being conducted during the 3-year program as part 
of process evaluation efforts. Data collection for program 
start-up occurred during August 2005 through September 
2006.  Data  include  approximately  70  interviews  with 
program  staff  and  stakeholders,  document  review,  and 
observations.  Both  case-specific  and  cross-case  analyses 
were conducted.
Results
On  the  basis  of  the  cross-case  analysis,  we  identified 
four factors that facilitated program start-up and four fac-
tors that challenged program start-up. Facilitating factors 
included 1) pre-existing program infrastructure, 2) part-
nerships, 3) clinical expertise, and 4) program champions. 
Factors challenging program start-up included 1) contracts 
with endoscopists, 2) resources for treating medical compli-
cations of screening and for cancer treatment, 3) adminis-
trative barriers, and 4) resource limitations. Additionally, 
preplanning was critical, allowing programs to efficiently 
initiate activities once funds became available.
Conclusion
The most important facilitator identified was the abil-
ity to build on pre-existing infrastructure, which provided 
experienced  staff,  partnerships,  and  provider  relation-
ships,  as  well  as  aided  program  integration  with  other 
chronic disease programs. Results also suggest that sub-
stantial planning and partnership development can begin 
before funds are secured to implement a colorectal cancer 
screening program.
Introduction
Colorectal  cancer  is  the  third  most  common  cancer 
among  both  men  and  women  in  the  United  States  (1). 
Although evidence suggests that regular colorectal cancer 
screening reduces colorectal cancer incidence and mortal-
ity (2), few organized, population-level screening programs 
have  been  implemented  and  evaluated  in  the  United 
States. Consequently, the Centers for Disease Control and 
Prevention (CDC) funded five Colorectal Cancer Screening 
Demonstration Program (CRCSDP) sites in 2005 for a 3-
year period (3).
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To assess the feasibility of providing community-based 
colorectal  cancer  screening,  CDC  is  conducting  a  mul-
tiple-case study (4,5) as part of a larger evaluation effort. 
Program evaluation is a critical function of public health, 
and demand continues to grow for evaluation to assess 
program implementation and effectiveness (6). The pur-
pose of the case study is to evaluate implementation of the 
CRCSDP and accurately describe how the program was 
carried out — that is, to understand what happened (7). 
Case study results are likely to offer valuable insights to 
others throughout the United States who are beginning to 
plan colorectal cancer screening programs.
We present case study findings for the start-up period, 
the time between initial program funding and initiation of 
screening services. Activities conducted during the start-
up  phase  of  the  CRCSDP  included  hiring  or  assigning 
staff; assembling medical advisory boards (MABs); devel-
oping program models, policies, and procedures; enlisting 
partners;  developing  data  collection  and  reporting  sys-
tems; planning client recruitment strategies; and identi-
fying resources for treating complications. A description 
of individual program models and start-up activities are 
detailed elsewhere (8). This manuscript presents results of 
a cross-case analysis and identifies the key facilitators and 
challenges to the start-up of CRCSDP sites.
Methods
We  conducted  a  multiple-case  study  (4,5)  during  the 
program start-up period as part of the process evaluation 
efforts. All CRCSDP sites were included in the case study, 
representing  five  unique  “cases.”  Participants  included 
grantee staff and stakeholders involved in program start-
up and CDC staff providing program oversight and tech-
nical assistance. Data were collected during August 2005 
through September 2006 and included document review, 
approximately  70  interviews,  and  field  observations. 
Atlas.ti (Atlas.ti Scientific Software Development GmbH, 
Berlin,  Germany),  a  software  program  for  qualitative 
data,  was  used  to  facilitate  analysis.  A  codebook  with 
detailed  code  definitions  was  developed,  and  standard 
content analysis (9) was used to make inferences from the 
data.
Given the multiple-case study design, we conducted both 
case-specific and cross-case analyses (4,5,10). To under-
stand each unique case, first we conducted individual case 
analysis (4,5). Cross-case analysis then was carried out to 
identify findings common across the five cases (4,5,10). 
A  detailed  account  of  the  methodology  is  summarized 
elsewhere (8).
Results
On  the  basis  of  the  cross-case  analysis,  we  identified 
four factors that facilitated program start-up and four fac-
tors that challenged program start-up. Facilitating factors 
were 1) pre-existing program infrastructure, 2) partner-
ships,  3)  clinical  expertise,  and  4)  program  champions. 
Challenges  to  program  start-up  were  1)  contracts  with 
endoscopists, 2) resources for treating medical complica-
tions and for cancer treatment, 3) administrative barriers, 
and 4) resource limitations.
Facilitators to program start-up
Pre-existing program infrastructure
The most important facilitator of program start-up was 
the use of pre-existing health program infrastructure, on 
which CRCSDP sites built to develop their colorectal can-
cer screening programs. Sources of infrastructure included 
the National Breast and Cervical Cancer Early Detection 
Program (NBCCEDP), the Well-Integrated Screening and 
Evaluation for Women Across the Nation (WISEWOMAN) 
program, other health initiatives such as prostate cancer 
screening programs, colorectal cancer screening programs 
in  other  parts  of  the  states,  previous  colorectal  cancer 
screening pilot programs, previous research assessments 
of  colorectal  cancer  screening  capacity,  and  structures 
and systems within the grantee institution itself (Table 
1). NBCCEDP and the  WISEWOMAN program are other 
CDC-funded screening programs for breast and cervical 
cancer  and  cardiovascular  health,  respectively  (11,12). 
Some of these efforts provided opportunities to gain expe-
rience in implementing public health screening programs, 
build  relationships  with  providers,  and  test  screening 
models well in advance of participating in the CRCSDP. 
All contributed to the readiness of each site to initiate the 
new CRCSDP.
The NBCCEDP was identified as an important frame-
work for program planning in four of the CRCSDP sites by 
offering structure, systems, and experience. The fifth site 
did not have experience with the NBCCEDP. The CRCSDP 
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(e.g.,  provider  system,  data  management  system)  and 
modified them to fit their new model for colorectal can-
cer screening. For instance, sites used their pre-existing 
NBCCEDP network of clinical providers to deliver screen-
ing services (e.g., distribute and process fecal occult blood 
test kits) and make referrals for colonoscopy. The sites also 
recruited MAB members from the NBCCEDP to establish 
a new MAB for the CRCSDP, they integrated colorectal 
cancer-related data management and billing into existing 
NBCCEDP systems, and they planned to recruit clients for 
colorectal cancer screening through “in-reach” (i.e., recruit-
ment of clients of an existing program). One stakeholder 
working with a provider site said, “When it came time to 
start policies, procedures, contracts, I think I had a leg up 
on that because of doing all of that with [NBCCEDP].”
Partnerships
Partnerships emerged as another important facilitator 
of program start-up, yielding benefits including technical 
support, expertise, and resources. Most important among 
partners were the Comprehensive Cancer Control (CCC) 
programs in the states with CRCSDP sites. CCC activities 
typically are coordinated by the state health department 
and engage a wide range of stakeholders to develop and 
implement statewide cancer control plans. In some cases, 
the CCC programs had planned well in advance of the 
CRCSDP initiative and provided important support dur-
ing the start-up period. A unique contribution of the CCC 
programs involved brokering access to a network of well-
established relationships, such as with leading colorectal 
cancer experts in the state who could be recruited for par-
ticipation on the MAB. In addition, individual members of 
the CCC programs were ready to support and advocate for 
the new colorectal cancer screening programs. One staff 
member said, “I don’t know if we could have had some of 
the doors open as wide and as quickly if we didn’t have the 
comp cancer program.” In addition, CCC groups provided 
instrumental in-kind staff support and financial resources 
to the CRCSDP sites.
For  two  of  the  sites,  CCC  programs  played  a  central 
role in applying for CRCSDP funds from CDC. One per-
son noted, “The [colorectal cancer task force of the CCC 
program] had come up with its own mission statement 
and vision, so there had been a lot of team building before 
the writing of the demo grant. It was a good foundation 
in order for us to move forward.” In addition, some of the 
CCC groups had been awarded competitive funds to host 
a Dialogue for Action, a day-long event sponsored by the 
Prevent Cancer Foundation and CDC to increase colorec-
tal cancer screening by convening providers, medical spe-
cialists,  researchers,  and  representatives  of  government 
and nongovernment agencies. These events had helped to 
mobilize providers, many of whom were later invited to 
participate in the CRCSDP.
Other  key  partners  included  the  American  Cancer 
Society  (ACS),  local  universities,  and  cancer  treatment 
centers  (Table  2).  In  one  site,  ACS  provided  important 
professional education materials to participating clinical 
provider sites. In another site, a local university helped 
to develop data collection forms and plan an evaluation of 
recruitment activities.
Clinical expertise
Interviewees  emphasized  the  value  of  having  clinical 
expertise  available  early  in  the  start-up  process.  Staff 
members  suggested  that  the  CRCSDP  was  more  medi-
cally complex than the NBCCEDP, which several program 
directors also managed. Clinical expertise came primarily 
from two sources: program staff and members of MABs. 
Individuals  with  expertise  in  the  delivery  of  colorectal 
cancer screening services assisted in developing program 
policies,  patient  flow  processes,  data  collection  systems 
and related forms, treatment plans, and quality assurance 
measures.
One staff member acknowledged the challenges of ini-
tiating the CRCSDP without access to in-house staff pos-
sessing clinical knowledge:
I felt like there needs to be more clinical expertise 
in the department. Because we didn’t have that, 
we really struggled. . . . [We] had difficulty under-
standing the various protocols associated with the 
tests and communicating with physicians and clini-
cians . . . so I think, would this program start over 
again, I would say you really need to have a clinical 
lead with expertise and background in this area.
Others  believed  their  staff  with  clinical  training  lent 
credibility to the new program and facilitated communica-
tion between the program and its MAB, as well as partici-
pating providers. One person said:
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I think you do need a clinical person. I don’t know 
that it has to be a physician, but I think you at 
least have to have a nurse to take a look to see 
that things are making sense. I also think that’s 
true when you’re talking with providers in terms of 
bringing them on board — they need to understand 
that you really know what you’re talking about.
Program champions
Program champions were another facilitator of program 
start-up. Although champions were identified at various 
levels,  the  program  directors  often  were  viewed  as  the 
overall  champion  during  start-up.  Their  understanding 
of the whole initiative, their ability to build relationships, 
and their reputation for past successes led others to want 
to be involved with the new CRCSDP. One physician on an 
MAB said, “I’ve worked with [the program director] previ-
ously . . . so she was a major reason for my participating 
on this project.”
Champions were identified at other levels of the pro-
gram as well. In several cases, programs engaged leading 
gastroenterologists in their state or region to participate in 
their MAB; these physicians often became champions for 
the program during the start-up period, offering legitima-
cy for the CRCSDP in the medical community. One staff 
member noted, “If other doctors hear that [MAB member] 
has okay’d something, or that he agrees with it, then they 
are okay with it because of his reputation and history of 
involvement with cancer issues.”
Champions  also  existed  at  individual  provider  sites, 
negotiating the bureaucracy of their own institutions to 
facilitate integration of the CRCSDP into their systems 
and build support for its implementation. One physician, 
acknowledging this role, remarked, “I see myself as a con-
sultant, a colon and rectal surgeon who knows the problem, 
who knows what surgeons do, what gastroenterologists do, 
what patients do, and what hard-headed institutions do 
who don’t want to yield.” These champions all exhibited 
important leadership and commitment toward ensuring 
the successful start-up of the CRCSDP.
Challenges to program start-up
Contracts with endoscopists
Contracting endoscopists to conduct colonoscopies proved 
to be a challenge for some sites. Staff and stakeholders 
identified the following barriers to endoscopists’ participa-
tion:  1)  burdensome  government  contracting  processes; 
2)  ethical,  financial,  and  liability  concerns  about  the 
lack of treatment for people diagnosed with cancer, even 
though  the  individual  programs  had  identified  sources 
for  treatment;  3)  capacity  limitations  among  providers; 
4) Medicare reimbursement rates being seen as low com-
pared with other insurance sources; 5) data and paper-
work requirements for the CRCSDP; 6) overall disruption 
to the endoscopist’s practice in integrating a small number 
of CRCSDP clients; and 7) concerns about poor compliance 
(e.g., no-shows, inadequate bowel preparation) in a low-
income client population.
One staff member acknowledged that, overall, endosco-
pists or their institutions might perceive the program to 
be too burdensome:
It’s sort of a balancing act . . . even with concerned 
physicians  [gastrointestinal  specialists]  who  are 
interested and want to do this systematic approach. 
It may not make sense when you look at it from the 
business manager’s side, or paperwork demands. 
The  [NBCCEDP]  program  disrupts  every  aspect 
of  a  program  from  medical  people,  billing  staff, 
contract people, all of them — our system disrupts 
their systems. It’s not really value added for them; 
there’s no advantage for them.
On the basis of their start-up experience, interviewees 
recognized the need to initiate relationships with endos-
copists early on, engaging them in the planning process 
from the start. One physician suggested, “You need to find 
somebody  [i.e.,  an  endoscopist]  who  has  the  passion  to 
understand the importance of screening and understands 
that it will cost them time that they may not be paid for, 
but that it’s the right thing to do.”
Resources for treating medical complications and 
for cancer treatment
Consistent with the NBCCEDP, CRCSDP funds could 
not  be  used  to  pay  for  cancer  treatment,  and  CDC 
required that sites applying to participate in the CRCSDP 
secure treatment resources as a condition of funding (13). 
Similarly, CDC funds could not be used to support the 
costs of treating unintended medical complications result-
ing  from  screening  examinations.  Although  resources 
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selected,  in  many  instances  these  resources  were  too 
limited  or  not  reliable,  raising  both  ethical  and  practi-
cal  concerns.  Program  staff  and  stakeholders  expressed 
apprehension about screening a population that could not 
pay for treatment and might not qualify for assistance. 
One staff member said, “There’s nothing more distressing 
for us or clinicians than to know that you have someone 
with  positive  results  [cancer],  but  there  is  no  funding 
mechanism available for treatment.”
Sites also faced the practical challenge of requesting no-
cost treatment services from local cancer centers and hos-
pitals or considering how best to facilitate clients’ applica-
tions for emergency Medicaid or other financial assistance. 
One  staff  member  noted,  “[Securing  resources  is]  very 
‘piecemeal.’ . . . We’ve had problems in our other program 
where we couldn’t get a patient on emergency care, and 
having to piece together surgery, chemo, pharmacy sup-
port, etc., is incredibly difficult.” In more rural settings, 
there  were  concerns  that  cancer  centers  in  the  largest 
cities would shoulder the burden for treatment. The lack 
of treatment resources also deterred some providers from 
participation in the CRCSDP, given their own ethical con-
cerns, as well as worries about a potential financial burden 
for their practice or institution.
To  address  this  challenge,  program  staff  emphasized 
the importance of developing partnerships with potential 
sources of cancer treatment, including cancer centers and 
hospital-based oncology departments. In several instances, 
MAB members facilitated these relationships. In addition, 
staff members suggested the need to identify more than 
one treatment provider to “share the burden.”
Administrative barriers
Administrative challenges such as hiring and retaining 
staff,  establishing  contracts,  and  developing  and  imple-
menting  data  and  billing  systems  led  to  delays  in  the 
start-up process. In one case, pay scales were blamed for 
the inability to hire a nurse coordinator and forced the 
program to alter its program model more than 2 months 
into the start-up period. In another, staff turnover in a 
key position left remaining staff to fill the void during a 
time-consuming hiring process. Contracting proved prob-
lematic for several CRCSDP sites, particularly for provid-
ers who had not worked with public agencies in the past. 
One staff member said, “Establishing new contracts with 
people we’ve never worked with before is more challeng-
ing. The [agency contract] is long and can shock potential 
contractors.”  Finally,  developing  the  data  management 
system  and  integrating  it  into  existing  service  delivery 
systems  was  time  consuming  and  challenging,  and  in 
some settings, the reporting requirements were perceived 
as burdensome. “We’re coming to [the providers] saying, 
‘For our 20 patients, can you give us a paper bill, fill out 
this special form, use a different appointment system than 
what you normally do, and by the way, can you also sit on 
our MAB?’ ”
Resource limitations
The final challenge to program start-up involved resource 
limitations.  Given  expectations  that  programs  would 
implement  screening  at  6  months,  the  CRCSDP  sites 
allocated a substantial portion of their first-year budget to 
screening costs and made difficult compromises in staffing 
and other program components. This left some sites rely-
ing primarily on existing staff (i.e., in-kind) supported by 
other program funds and with other responsibilities. One 
staff person said, “The CCC has basically evolved in sup-
porting the CRC program for the past 2 years. If we hadn’t 
had that ability to move staffing responsibilities around, 
I’m not sure we would have wanted to start the project.” 
Another  staff  person  emphasized  the  importance  of  in-
kind contributions: “If CDC gets all this information back 
and thinks that what we’re actually spending to make this 
program work is what it would actually cost, then they’re 
not in line. . . . I was surprised though with what we were 
able to accomplish with the funding we got.” On the basis 
of the start-up experience, staff members suggested that 
financial  resources  should  be  obligated  to  support  key 
coordinating positions for the program.
Discussion
We  identified  several  important  facilitators  for  pro-
gram start-up, including using pre-existing infrastructure, 
building  partnerships,  engaging  clinical  expertise,  and 
involving strong champions. Of these, the use of pre-exist-
ing  infrastructure  was  the  most  valuable  in  advancing 
the start-up of the CRCSDP. Attempts to integrate the 
CRCSDP  with  other  chronic  disease  programs  such  as 
the NBCCEDP, WISEWOMAN, and other screening pro-
grams are consistent with broader calls in public health 
to move from “silo-funded” categorical programs to a more 
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integrated model (14). This integration has the potential 
to increase efficiencies in staff, funds, and interventions 
(14). Most importantly, clients served through these types 
of integrated programs may benefit from receiving a com-
prehensive array of screening services.
Results also suggest that critical planning for colorectal 
cancer  screening  and  related  partnership  building  had 
been  conducted  by  sites  even  before  the  CDC  funding 
opportunity arose. This work seemed to position the pro-
grams to compete successfully for the CRCSDP award and 
to move more quickly through the start-up period to initi-
ate screening. These results suggest that even for states 
with  minimal  or  no  funding  yet  available  for  colorectal 
cancer  screening,  important  planning  and  partnership 
development  can  be  accomplished  to  prepare  for  future 
opportunities. Once funding is secured, such efforts are 
likely to both shorten the time needed for program start-up 
and support its success. Furthermore, programs can build 
partnerships with clinical experts and potentially dimin-
ish challenges related to contracting with endoscopists if 
relationships with these providers can be established early 
in the planning process and their support enlisted.
Champions  emerged  as  important  in  negotiating  the 
multi-organizational  character  of  the  CRCSDP  service 
delivery environment. Given the full continuum of screen-
ing and diagnostic services (e.g., client recruitment, assess-
ment,  screening,  patient  navigation,  cancer  treatment) 
offered  through  the  CRCSDP,  sites  developed  program 
models  that  involve  a  networked  system  of  agencies  or 
departments, each providing a unique service or services 
within that continuum (8). This type of interagency col-
laboration  to  support  the  CRCSDP  is  increasingly  rec-
ognized  as  important  in  the  broader  implementation  of 
public health programs (15). The strong facilitative skills 
of the directors and coordinators of these colorectal cancer 
screening programs were essential to effectively engage 
stakeholders, build partnerships, negotiate common goals, 
and produce a well-designed program. These skills have 
been  recognized  in  the  public  management  and  public 
health literature as increasingly important to successful 
program management (16-18).
Our  findings  also  highlight  concerns  about  securing 
resources  for  treating  unanticipated  complications  of 
screening  and  for  treating  cancer  in  an  uninsured  and 
underinsured  population.  The  NBCCEDP  experienced 
similar challenges before the National Breast and Cervical 
Cancer Prevention and Treatment Act of 2000 (19); those 
programs  largely  succeeded  in  securing  treatment  for 
women  diagnosed  with  breast  and  cervical  cancer,  but 
not without substantial difficulty (20). A more permanent 
solution to securing treatment resources would benefit an 
expanded colorectal cancer screening program.
Finally, results suggest that reliance on staff with com-
peting  programmatic  responsibilities  may  further  chal-
lenge program start-up. Given the intensive effort required 
to develop the CRCSDP, allocating adequate resources for 
dedicated staff is important. This may be especially crucial 
given the clinical complexity of the program, the involve-
ment  of  multiple  provider  specialties,  and  the  compre-
hensive range of services provided (e.g., public education, 
outreach, screening, patient navigation).
Although  these  findings  represent  only  five  sites,  the 
identified facilitators and challenges to program start-up 
provide  important  information  for  other  emerging  pro-
grams. The facilitators were common across all CRCSDP 
sites in supporting the start-up of the CRCSDP, and a new 
program is likely to struggle without attending to each. 
In contrast, some of the challenges (e.g., contracts with 
endoscopists, administrative barriers) are more likely to 
be site-specific, depending on the unique characteristics 
of the program and its context, and others (e.g., resources 
for  treatment)  may  reflect  system-level  challenges.  The 
formative evaluation conducted through this case study 
is  yielding  results  that  provide  information  for  ongoing 
program improvement and for more widespread screen-
ing efforts in the future. Subsequent reports will provide 
evaluation  findings  from  the  screening  implementation 
phase of the CRCSDP.
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Tables
Table 1. Sources and Contributions of Pre-existing Infrastructure Used by the Colorectal Cancer Screening Demonstration 
Program, 2005–2006
Source of Infrastructure Contributions of Infrastructure
National Breast and Cervical Cancer Early Detection Program (NBCCEDP) 
and Well-Integrated Screening and Evaluation for Women Across the Nation 
(WISEWOMAN)
Network of clinical providers
Data management and billing systems




Staff experience and capacity
Other health or screening initiatives  Staff experience and capacity
Client base for colorectal cancer screening
Provider relationships
Other colorectal cancer screening programs in the state, previous colorectal 
cancer screening pilots, or research
Staff experience and capacity




Policies and procedures 
Patient referral systems
Grantee institution Clinical expertise 
Network of clinical providers
Cancer treatment resources
Table 2. Partner Involvement in Start-Up of the Colorectal Cancer Screening Demonstration Program, 2005–2006
Partner Activities
Comprehensive cancer control programs Planning, advocating, and identifying medical advisory board members; brokering partnerships; hosting 
Dialogue for Actiona; and providing in-kind and financial resources
Colorectal cancer task forces Planning, grant writing, and advocacy
American Cancer Society Identifying medical advisory board members; providing educational materials; and conducting public 
education campaigns, outreach efforts, and client recruitment
Local universities Developing data collection forms and public education materials and conducting evaluations
Cancer treatment centers Providing cancer treatment services
 
a A day-long event sponsored by the Prevent Cancer Foundation and Centers for Disease Control and Prevention to increase colorectal cancer screening by 
convening providers, medical specialists, researchers, and representatives of government and nongovernment agencies.
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